Low-dose probenecid selectively inhibits urinary excretion of phenolsulfonphthalein in rats without affecting biliary excretion

Journal of Applied Toxicology

Volumn 33, Issue 6, 2013, Pages 511-515

  Shin, Yong Jun ^a   Lee, Joo Hyun ^a   Oh, Ju Hee ^a   Lee, Young Joo ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Biliary excretion; Inhibitor; Phenolsulfonphthalein; Probenecid; Urinary excretion

Indexed keywords

PHENOLSULFONPHTHALEIN; PROBENECID;

ANIMAL EXPERIMENT; ARTICLE; BILIARY CLEARANCE; BILIARY EXCRETION; CLEARANCE; CONTROLLED STUDY; DRUG CLEARANCE; KIDNEY CLEARANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ANIMALS; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; BILIARY TRACT; COLORING AGENTS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY; LIVER; ORGANIC ANION TRANSPORTERS; PHENOLSULFONPHTHALEIN; PROBENECID; RATS; URICOSURIC AGENTS;

RATTUS;

EID: 84876710482     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1778     Document Type: Article

References (37)

1. Chen J, Lin H, Hu M. 2005. Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother. Pharmacol. 55: 159-169.
2. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. 2004. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res. 64: 3296-3301.
3. Despopoulos A. 1971a. Hepatic and renal excretory metabolism of bile salts: a background for understanding steroid-induced cholestasis. J. Pharmacol. Exp. Ther. 176: 273-283.
4. Despopoulos A. 1971b. Congruence of renal and hepatic excretory functions: sulfonic acid dyes. Am. J. Physiol. 220: 1755-1758.
5. Eraly SA, Vallon V, Vaughn DA, Gangoiti JA, Richter K, Nagle M, Monte JC, Rieg T, Truong DM, Long JM, Barshop BA, Kaler G, Nigam SK. 2006. Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J. Biol. Chem. 281: 5072-5083.
6. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P. 2000. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer 83: 375-383.
7. Fleck C, Braunlich H. 1987. Relation between renal and hepatic excretion of drugs. IV. Influence of nephrectomy or bile duct ligation on the accumulation of phenol red in kidney and liver tissue of rats of different ages. Exp. Pathol. 31: 205-219.
8. Gabel RA, Ranaei RA, Kivlighn SD. 1996. A new method of measuring renal function in conscious rats without the use of radioisotopes. J. Pharmacol. Toxicol. Meth. 36: 189-197.
9. Horikawa M, Kato Y, Tyson CA, Sugiyama Y. 2002. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab. Pharmacokinet. 17: 23-33.
10. Inoue M, Koyama H, Nagase S, Morino Y. 1985. Renal secretion of phenolsulfonphthalein: analysis of its vectorial transport in normal and mutant analbuminemic rats. J. Lab. Clin. Med. 105: 484-488.
11. Itagaki S, Sugawara M, Kobayashi M, Miyazaki K, Iseki K. 2003a. Mechanism of active secretion of phenolsulfonphthalein in the liver via Mrp2 (abcc2), an organic anion transporter. Drug Metab. Pharmacokinet. 18: 238-244.
12. Itagaki S, Sugawara M, Kobayashi M, Miyazaki K, Iseki K. 2003b. Mechanism of active secretion of phenolsulfonphthalein in the liver via Mrp2 (abcc2), an organic anion transporter. Drug Metab. Pharmacokinet. 18: 238-244.
13. Itagaki S, Shimamoto S, Sugawara M, Kobayashi M, Miyazaki K, Hirano T, Iseki K. 2005. Phenolsulfonphthalein transport by potential-sensitive urate transport system. Eur. J. Pharmacol. 518: 83-89.
14. Kudo N, Katakura M, Sato Y, Kawashima Y. 2002. Sex hormone-regulated renal transport of perfluorooctanoic acid. Chem. Biol. Interact. 139: 301-316.
15. Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Drusano GL, Sorgel F. 2009. Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid. Antimicrob. Agents Chemother. 53: 3902-3907.
16. Lew HS, Lee EC, Lee KS, Hong SK. 1962. Urinary and biliary excretion of dyes in acidosis and alkalosis in the dog. Am. J. Physiol. 203: 644-648.
17. Mano Y, Usui T, Kamimura H. 2007. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm. Drug Dispos. 28: 13-18.
18. Minematsu T, Hashimoto T, Aoki T, Usui T, Kamimura H. 2008. Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats. Drug Metab. Dispos. 36: 1496-1504.
19. Mukai T, Mera K, Nishida K, Nakashima M, Sasaki H, Nakamura J. 2004. Pharmacokinetics of phenol red in rat models of liver damage prepared by liver targeting of carbon tetrachloride. Biol. Pharm. Bull. 27: 595-597.
20. Nagata Y, Kusuhara H, Endou H, Sugiyama Y. 2002. Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol. Pharmacol. 61: 982-988.
21. Namkoong EM, Kim IW, Kim DD, Chung SJ, Shim CK. 2007. Effect of probenecid on the biliary excretion of belotecan. Arch. Pharm. Res. 30: 1482-1488.
22. Overbosch D, Van Gulpen C, Hermans J, Mattie H. 1988. The effect of probenecid on the renal tubular excretion of benzylpenicillin. Br. J. Clin. Pharmacol. 25: 51-58.
23. Russel FG, Wouterse AC, van Ginneken CA. 1987. Physiologically based pharmacokinetic model for the renal clearance of phenolsulfonphthalein and the interaction with probenecid and salicyluric acid in the dog. J. Pharmacokinet. Biopharm. 15: 349-368.
24. Shitara Y, Sato H, Sugiyama Y. 2005. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45: 689-723.
25. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y. 2001. Characterization of the efflux transport of 17beta-estradiol-d-17beta-glucuronide from the brain across the blood-brain barrier. J. Pharmacol. Exp. Ther. 298: 316-322.
26. Sun H, Miller DW, Elmquist WF. 2001. Effect of probenecid on fluorescein transport in the central nervous system using in vitro and in vivo models. Pharm. Res. 18: 1542-1549.
27. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK. 2002. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J. Biol. Chem. 277: 26934-26943.
28. Turner KC, Brouwer KL. 1997. In vitro mechanisms of probenecid-associated alterations in acetaminophen glucuronide hepatic disposition. Drug Metab. Dispos. 25: 1017-1021.
29. Ueda K, Kato Y, Komatsu K, Sugiyama Y. 2001. Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J. Pharmacol. Exp. Ther. 297: 1036-1043.
30. Uwai Y, Saito H, Inui K. 2000. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur. J. Pharmacol. 409: 31-36.
31. Van Aubel RAMH, Masereeuw R, Russel FGM. 2000. Molecular pharmacology of renal organic anion transporters. Am. J. Physiol. Renal Physiol. 279: F216-F232.
32. Vlaming ML, Lagas JS, Schinkel AH. 2009. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv. Drug Deliv. Rev. 61: 14-25.
33. Ward ES, Pollack GM, Brouwer KL. 2000. Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? Drug Metab. Dispos. 28: 1433-1439.
34. Xia CQ, Milton MN, Gan LS. 2007. Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr. Drug Metab. 8: 341-363.
35. Yang B, Hill CE. 2001. Nifedipine modulation of biliary GSH and GSSG/conjugate efflux in normal and regenerating rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G85-94.
36. Zakeri-Milani P, Barzegar-Jalali M, Tajerzadeh H, Azarmi Y, Valizadeh H. 2005. Simultaneous determination of naproxen, ketoprofen and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. J. Pharm. Biomed. Anal. 39: 624-630.
37. Zimmerman HJ. 1999. Hepatotoxicity: the Adverse Effects of Drugs and Other Chemicals on the Liver. Lippincott Williams & Wilkins: Philadelphia; 297.